David Hamilton at VentureBeat has an article on XDx, a molecular diagnostic company focusing on gene expression tests, which just filed for an IPO to raise as much as $87 million. The article lays out the case for gene-expression-based diagnostics, but also notes that so far these tests have "been slow to catch on." The article runs through similar existing tests, and gives a nice snapshot of the XDx business.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.